Which funds bought or sold SNY in Q3 2026?
Sanofi Sa Adr. 2 funds bought, 4 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$553M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Pzena+$4M
- Maverick+$2M
- Dodge & Cox−$512M
- Balyasny−$95M
- Fisher Investments−$42M
- GQGOUT−$4M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (2)
Sold (4)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Dodge & Cox Value investor | Trimmed-44.2% | −$512M | $646M |
| Balyasny Quant & multi-strategy | Trimmed-95.9% | −$95M | $4M |
| Fisher Investments Asset manager | Trimmed-9.7% | −$42M | $396M |
| GQG Growth / crossover | Sold out | −$4M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.